Trial Profile
A PHASE 1B, RANDOMIZED, DOUBLE-BLIND (SPONSOR-OPEN), PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF MULTIPLE ORAL DOSES OF PF- 06865571 FOR 2 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2020
Price :
$35
*
At a glance
- Drugs Ervogastat (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 29 Apr 2019 Status changed from recruiting to completed.
- 25 Mar 2019 Planned End Date changed from 5 Apr 2019 to 11 Apr 2019.
- 18 Feb 2019 Planned End Date changed from 20 Feb 2019 to 5 Apr 2019.